Dr. Andrea van Elsas
Andrea van Elsas brings extensive experience as a researcher and entrepreneur. He received his PhD in 1996 from the University of Leiden. He performed his post-doctoral research at the University of California, Berkeley, studying antibodies blocking CTLA-4 for the treatment of cancer and is a co-inventor on the original patents that formed the basis for the development of Yervoy(r) (ipilimumab), the first checkpoint inhibitor approved in 2011 by the U.S. Food and Drug Administration for the treatment of melanoma. He held numerous positions at Organon in Oss, Netherlands, and Cambridge, Massachusetts (acquired by Schering-Plough Corporation in 2007 and later by Merck & Co.), and as the Director of Tumor Immunology he ran the immune oncology portfolio including the program that later became known as pembrolizumab. Dr. Andrea van Elsas co-founded BioNovion and served as Chief Scientific Officer focusing on the development of innovative therapeutic antibodies in the field of immune oncology. Aduro Biotech acquired Bionovion in 2015 and Andrea became Chief Scientific Officer of Aduro Biotech Europe.
Andrea assists Gilde in the evaluation of investment opportunities and is also acting as VP of Research for Gilde's portfolio company AM Pharma.